Early combined immunosuppression in Crohn's disease

The Lancet

Volumn 371, Issue 9629, 2008, Pages 1995-

  Badina, Laura ^a   Taddio, Andrea ^a   Ventura, Alessandro ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

CANCER RISK; CROHN DISEASE; DISEASE ACTIVITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; PRIORITY JOURNAL; REMISSION; T CELL LYMPHOMA; DRUG ADMINISTRATION; DRUG COMBINATION; NOTE;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 44849125742     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60860-0     Document Type: Letter

References (5)

1. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008) 660-667
2. Punati J., Markowitz J., Lerer T., et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis (2008) 10.1002/ibd.20412 published online Feb 27.
3. Lichtenstein G., Abreu M., Cohen R., Tremaine W., and American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 (2006) 940-987
4. Behm B., and Bickston S. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 1 (2008) CD006893.
5. Mackey A., Green L., Liang L., Dinndorf P., and Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 (2007) 265-267